SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Aurisco Pharmaceutical Co., Ltd (Aurisco), a science-based, USFDA inspected CRDMO and cGMP generic API manufacturer, announced today that members of its senior management are scheduled to participate and exhibit, until the end of the year, in the following upcoming conferences and tradeshows:
YANGZHOU, China, Aug. 15, 2023 /PRNewswire/ -- Aurisco Pharmaceutical announced today that its API and FDF plant in Yangzhou, China has successfully passed a cGMP inspection by the US Food and Drug Administration (USFDA).
SHANGHAI, June 27, 2023 /PRNewswire/ -- Aurisco Pharmaceutical has good reasons to celebrate. On its 25th anniversary, the high-tech pharmaceutical company dedicated to innovation has received its first Marketing Authorization Approval in China for AUXITON®, the oral finished dosage form of Dydrogesterone, from China's Health Authority, the NMPA. Aurisco is the only company holding both an active USDMF and a valid CEP – the Certificate of compliance with the European Pharmacopoeia, issued by the EDQM for the drug substance.
SETÚBAL, Portugal, April 20, 2023 /PRNewswire/ -- On its 25th anniversary, Aurisco Pharmaceutical, an innovative pharmaceutical CRDMO (contract research, development and manufacturing organization) announced the expansion of its oligonucleotide manufacturing capacity and a new edition of its corporate website – www.aurisco.com.
Aurisco cooperates with Cytiva to build its first Oligo FlexFactory for commercial production
Aurisco, a pharmaceutical company and contract development and manufacturing organization (CDMO) in China, is cooperating with global life sciences company Cytiva, to build its first Oligo FlexFactory platform for commercial production.
Johnson & Johnson‘s (NYSE:JNJ) subsidiary Auris Health today released preliminary results from a first-in-human feasibility study of its Monarch robotic interventional platform, which has FDA clearance for diagnostic and therapeutic bronchoscopic procedures.